“They’re looking for scapegoats.” — Aaron Kelly, PhD, of the University of Minnesota in Minneapolis, on the American Diabetes Association’s final report about five scientists ousted from this year’s annual meeting.
“So 130 years later, we’re still trying to work out what to do with it.” — Hugh Gallagher, MBBS, PhD, of Epsom and St Helier University Hospitals NHS Trust in England, after low-dose aspirin failed to reduce major vascular events in a trial of adults with chronic kidney disease.
“Something we have not seen for years.” — Nathalie Gaspar, MD, PhD, of Gustave Roussy in Villejuif, France, on positive phase III trial results for an investigational osteosarcoma drug tested in adolescents and adults.
“It concerns me that there was a frame shift or some sort of systemic error in how the data were collected.” — Aaron Gans, MD, who received an “indeterminate” score on his internal medicine board exam after widespread software glitches.
“The limitation is not the biological absence of sperm for these cases.” — Hemant Suryawanshi, PhD, of Columbia University Fertility Clinic in New York, discussing an artificial intelligence-powered tool designed to identify ultra-rare sperm in men with azoospermia.
“It’s not clear what the fix is, but the current system is creating a lot of friction.” — Joe Antos, PhD, of the American Enterprise Institute, on hurdles to reforming the No Surprises Act.
“We as a medical community still have work to do in growing that awareness further.” — Jay Davis, MD, of the University of Colorado Anschutz Medical Campus in Aurora, on potential interactions between GLP-1 drugs and lithium.
“The increase … is likely not just due to hemoconcentration.” — Michele Eisenga, MD, PhD, of University Medical Center Groningen in the Netherlands, on data linking SGLT2 inhibitors with increases in hemoglobin and hematocrit levels.
